Market Information
Asia Pacific

The Biotechnology Market
in Hong Kong

June 2002

© Department of Foreign Affairs and International Trade
Faxlink #42591

Report prepared by the Market Research Centre
Market Support Division (TCM)
Department of Foreign Affairs and International Trade
125 Sussex Drive, Ottawa K1A 0G2
Fax: (613) 943-1103
E-mail: mrc@dfait-maeci.gc.ca

The Market Research Centre produces a wide range of market reports by region and sector for Canadian exporters. These reports are available from:
- DFAIT's InfoExport Internet site (http://www.infoexport.gc.ca).

The Government of Canada has prepared this report based on primary and secondary sources of information. Readers should take note that the Government of Canada does not guarantee the accuracy of any of the information contained in this report, nor does it necessarily endorse the organizations listed herein. Readers should independently verify the accuracy and reliability of the information.

Quick Facts

Market Highlights

• Hong Kong is strategically located as a gateway to the Chinese market for biotechnology and pharmaceutical products. In fact, the Chinese market accounts for 68% of all Hong Kong exports of pharmaceuticals and medical equipment.
• The biotechnology industry in Hong Kong is small but has a solid research base to support growth.
• There has been recent growth in downstream research and product commercialization, as well as private sector investment.

Opportunities

• Canadian companies should consider the opportunities presented by Hong Kong as an access point for the large Mainland Chinese market.
• There are opportunities in the Hong Kong biotechnology market for Canadian companies to licence technology with commercial potential or partner with local research institutions on promising technology.
• Canadian biotechnology companies with expertise in drug discovery, bio-agriculture and natural compounds technology may benefit from collaborative partnerships with traditional Chinese medicine specialists and investors in Hong Kong.

Key Players

• Multinational pharmaceutical and biotechnology companies dominate the Hong Kong biotechnology industry.
• Local players are active in biomedical research, gene chip technology and some agricultural biotechnology research.

Export Checklist

• There are no significant regulatory or legal barriers for Canadian firms when conducting business in Hong Kong.
• All pharmaceutical and biopharmaceutical products must be registered in Hong Kong and agricultural biotechnology regulations are currently incomplete.
• As regulations differ in the Mainland, companies should work closely with their Hong Kong partner to ensure that the proper steps have been taken.

Market Summary

• Hong Kong is a Special Administrative Region (SAR) of China and has been granted autonomy in matters of finance and justice. Defence and international relations are controlled by the Chinese central authority.
• According to the Economist Intelligence Unit (EIU), Hong Kong is known as a trading centre. It has limited natural resources and is dependent on imports for most raw materials, food, fuel, pharmaceuticals and other products. Banking, trade, tourism and other service industries are responsible for the bulk of Hong Kong's economic output. The wealth of financial, legal, accounting and other service sector specialists in the area provide critical partners in the growth of Hong Kong's biotechnology industry.
• Hong Kong is strategically located and poised to benefit from China's accession to the World Trade Organization. With a more open trade regime in China, Hong Kong will serve as a gateway to the Chinese market. The EIU predicts that Hong Kong's real GDP will grow by 2.8 percent in 2002 and increase by as much as 6.3 percent in 2003.
• According to the Innovation and Technology Commission (ITC)¹ of Hong Kong, there are approximately 200 companies active in the pharmaceutical (including traditional Chinese medicines) and biopharmaceutical sectors. In 1997, domestic output was approximately $300 million² (over half of which was exported) and the sector employed 2400 people.
• The entire pharmaceutical market in Hong Kong had an estimated value of $1.1 billion in 1999. Advanced medications are typically imported while generic and traditional Chinese medications (TCM) are produced locally. There are 61 licensed manufacturers of western drugs in Hong Kong, most of which produce generics.
• China is the leading export market for Hong Kong's pharmaceutical and medical equipment exports, accounting for 68% of exports. As the biotechnology industry develops in Hong Kong, China will continue to be the primary export market for products and services.
• The biotechnology industry in Hong Kong is small, with a few products ready for commercialization. Biotechnology companies in Hong Kong can be categorized into large multinational pharmaceutical firms with biotechnology divisions, local startups, divisions of local conglomerates, divisions of mainland Chinese companies, and equipment and reagent suppliers.
• Key biotechnology sectors in Hong Kong include biopharmaceuticals; environmental, food and agriculture applications; and traditional Chinese medicines.
• Hong Kong has strong infrastructure and research institutions to support the biotechnology industry and although these necessary elements are present, little has developed in terms of technology licencing, downstream research and product commercialization. One of the challenges facing the biotechnology industry in Hong Kong is the lack of private investment in start-up companies. These long-term investments are essential to support growth in the industry, but investors in Hong Kong are still hesitant to invest in companies who may be many years away from product commercialization.
• The small number of research companies active in the market also presents problems for highly qualified graduates from Hong Kong's various research centres. With a limited number of positions available, many qualified scientists leave Hong Kong and seek out opportunities in other parts of the world.

Medical Biotechnology

• In Hong Kong, an estimated 75% of the population indicate that they consult traditional practitioners (i.e. TCM) for a number of health conditions.
• Biotechnology in Hong Kong is currently focused on the drugs and medicines sector, including TCM. The bulk of the industry's exports are shipped to mainland China and to other smaller regional markets like Malaysia, Macau and Singapore.
• The Hong Kong government has banned all forms of cloning and human stem cell research is strictly limited to fertilized eggs which have divided into four cells. The Human Reproductive Technology Council is set to review requests by scientists to re-visit these limits on stem cell research, but as of April 2002, no new regulations had been released.
• As a result of the restrictions on human stem cell research, very little of it is conducted in Hong Kong. Scientists hope a review of current regulations will loosen the restrictions to allow for research on embryos of up to 100 cells and see a niche sector develop in Hong Kong. Currently scientists in the region are working on mouse embryos and publishing high level results.
• Areas of growth for the pharmaceutical and biopharmaceutical industries in Hong Kong will be cardiovascular, lifestyle and oncology medications as well as treatments that respond to conditions typical in an aging population including arthritis, diabetes, osteoporosis and diseases of the central nervous system.

Agricultural Biotechnology

• The primary emphasis of the Hong Kong biotechnology industry is biomedical applications, however, a few companies and research institutes are working on specific projects in the agricultural biotechnology field.
• University researchers in Hong Kong signed research cooperation agreements with scientists in Taiwan and Mainland China in the field of agricultural biotechnology. At a conference in Hong Kong in September 2001 academics agreed to continue work in the field and agreed that DNA technology was critical for future food supply demands in Asia and internationally.
• Primary areas of activity in agricultural biotechnology in Hong Kong include crop improvements, the use of plants as bioreactors, developing vaccine and medicine delivery mechanisms in fruit and vegetables, and genomic analysis of crops critical to Asian economies.

Government Support for Biotechnology

• The government of Hong Kong is a strong supporter of biotechnology and sees the industry as a key component for economic growth in Hong Kong. As a result, the government has invested heavily in biotechnology, primarily through the Innovation and Technology Commission. The primary recipients have been Hong Kong University, the Chinese University of Hong Kong and the Hong Kong University of Science and Technology. Approximately $150 million was invested in biotechnology between 1994 and 1999.
• As well as a centre of research excellence and product development, the government also hopes to position Hong Kong as a regional hub for biotechnology products and services.

Key Research Centres

• The university system in Hong Kong has strong research programs in biotechnology, research that is ready for transfer to companies for downstream research and eventual commercialization as well as a number of young scientists capable of starting spin-off companies.The strength of these research institutions is key for the development and sustained growth for the biotechnology industry in Hong Kong. To date, however, the domestic industry has been slow to take advantage of the technology developed in the research institutions. As a result, the government has sought out ways to facilitate the transfer of research into commercial applications.
• The Hong Kong Institute of Biotechnology (HKIB) is a self-financing downstream development centre for biotechnology products and is recognized as one of the leading technology and manufacturing centres for vaccines and pharmaceuticals in Asia. With grants from the Hong Kong Government's Industrial Support Fund and the World Health Organization, HKIB has established a manufacturing plant to produce clinical trial material for human vaccines and biopharmaceuticals under global Good Manufacturing Practices (GMP) guidelines.
• In 1997, HKIB established the Hong Kong Pharmaceutical Technology Centre (HKPTC), which provides technical support services on GMP implementation to the local pharmaceutical industry to assist with upgrades of manufacturing processes so that the products can be exported worldwide.
• HKIB also has a plant biotechnology program that focuses on the development of cost-effective micro-propagation processes for traditional Chinese medicines and ornamental plants. HKIB's process development facility for extraction and concentration of TCM compounds is intended as a step in the downstream development of health food and pharmaceuticals based on traditional remedies. HKIB hopes to position Hong Kong and the process development facility as a world centre for the development pharmaceuticals, biopharmaceuticals, and health foods based on TCM.
• The Biotechnology Research Institute (BRI) is affiliated with the Hong Kong University of Science and Technology (HKUST). The institute's four key research sections are traditional Chinese medicine, protein engineering and design, plant biotechnology and neuro-proteins. Key disease areas for research include neuro-degenerative diseases, pain and drug addiction, stroke, epilepsy, cancer, immune system enhancement and the role of anti-oxidation. BRI is also active in forming international partnerships and collaborative research programs.

Recent projects include:

• In collaboration with HKUST, ITC and Chinachem Group, BRI has developed gene chips to more accurately test the identity of traditional Chinese medicines and at a reasonable price. The technology will have additional applications in DNA analysis for the biotechnology industry. BRI is one of the few institutions in Hong Kong currently using gene chips and plans to seek contract opportunities in medical diagnostics, biomedical research, drug discovery, genomics research, and genetic testing.
• In the field of TCM, BRI is using traditional knowledge as well as moderndrug discovery techniques to systematically screen TCM products and botanicals for therapeutically active compounds.
• BRI is working, in partnership ITC and VivoQuest Inc. (with offices in New York and Hong Kong) to create combinatorial libraries based on TCM compounds. The project will result in a series of libraries based on combinatorial chemistry analysis of TCM products. The libraries will aid in the drug discovery process by identifying lead compounds based on specific inputs. Once established, BRI will seek licensing opportunities with international biotechnology companies and other institutions.
• Also, in partnership with ITC and VivoQuest, BRI is developing a highthroughput screening center for TCM. The project is designed to increase high-throughput screening capacity in Hong Kong and to further contribute to identifying novel drug leads from TCM compounds. The centre will also serve as a contract screening facility for the region and for international companies.
• In order to further develop TCM products, BRI has partnered with ITC and Kinetana Hong Kong Herbal Pharmaceutical Ltd. to create an artificial gut to process and manufacture TCM compounds. Kinetana is a subsidiary of Edmonton-based Kinetana Group Inc.
• BRI has begun a standardization and certification program for traditional Chinese medicines with sponsorship from ITC, Winsor Health Products Ltd. (Hong Kong), Pharmanex (Utah), and New World China Enterprises Projects Ltd. (China). In collaboration with the Chinese University of Hong Kong, the Hong Kong Baptist University, the Hong Kong University, ASTRI, HKIB and the international experts (Massachusetts Institute of Technology, the University of North Carolina at Chapel Hill), BRI is developing guidelines to standardize and certify Chinese medicines at the Institute of Chinese Medicine (ICM).
• The Applied Science and Technology Research Institute Co. Ltd. (ASTRI) was recently established by the government to stimulate growth of technology-based industries in Hong Kong. ASTRI is to act as a midstream research centre in an effort to bridge the gap between academic research and downstream commercialization. With investors unwilling to invest in early stage projects ASTRI is an attempt by the government to incubate and develop promising technologies before transferring them to the commercial sector. The government hopes to see a strong cluster of biotechnology research companies established in the Hong Kong Science Park.
• The Applied Research Centre for Genomic Technology at the City University of Hong Kong is focused on biomedical research for regional specific conditions including liver cancer and hepatitis infection. The centre has facilities to produce gene chips to test for diseases and individual genetic conditions.
• The City University of Hong Kong is also home to the Area of Excellence on Plant and Fungal Biotechnology. The centre is dedicated to crop improvement research, functional genomics in agricultural systems, fungal biotechnology and the use of plants as bioreactors.

Opportunities

• While there is a demand for biotechnology products and services in Hong Kong, Canadian companies may also want to consider the potential presented by the SAR as a launch pad from which to access the Mainland Chinese market. Hong Kong has an impressive concentration of experienced contacts and business expertise in the Chinese market.
• There are opportunities in the Hong Kong biotechnology market for Canadian companies to licence technology with commercial potential. Downstream research and commercialization of biotechnology products has traditionally been weak in Hong Kong and represents opportunities for Canadian companies to partner with local research institutions or simply licence promising technology.
• The effectiveness of traditional Chinese medicines and the potential for new drug development is gaining global recognition. Many of the recent projects sponsored by the Hong Kong's Innovation Technology Commission and local research centres focus on the potential of TCM. Canadian biotechnology companies with expertise in drug discovery and natural compounds may benefit from collaborative partnerships with TCM specialists in Hong Kong.

Key Players

• Multinational pharmaceutical and biotechnology companies dominate the Hong Kong biotechnology industry. Companies with offices in Hong Kong include United States based Merck Research Laboratories, Pfizer Pharmaceutical Inc., Monsanto Corp., and VivoQuest Inc., as well as GeneScan Europe AG based in Germany and Switzerland based Novartis. Eli Lilly (US) established its Asian headquarters in Hong Kong in 2001 in order to take advantage of the SAR's unique relationship with Mainland China.
• Local players in the biotechnology market in Hong Kong include the following:
• Alberta Economic Development announced in December 2001 that a portion of the $2 billion being invested in the Hong Kong biotechnology industry by CK Life Sciences will be directed to biofertilizer research in the province.
• Genetel Pharmaceuticals is developing DNA microarrays to detect obesity and osteoporosis genes. The company is seeking to combine modern genomic analysis with traditional Chinese medicines to find drug targetsand lead compounds.
• Hong Kong DNA Chips is a gene chip company looking to develop diagnostic tools for both detection and diagnosis of hepatitis, HIV and the human papilloma virus among others. In order to raise funds for biomedical applications and research, the company offers testing services for genetically modified organisms as well as DNA fingerprinting to determine paternity and test kits for avian viruses.
• Agritech is an agricultural biotechnology company which has developed a slow ripening tomato. The modified tomatoes can be stored for up tothree months without spoiling.
• Maxx Bioscience Technology is a technology incubator that is looking to go public by the middle of 2002. The company helps clients enter the Mainland Chinese market by providing both business and biotechnology expertise. As well, the company is looking to acquire a majority stake in HKIB's drug manufacturing operations.
• Advanced Genes in a Hong Kong based companies with an office in Shenzhen working on growth-stimulants for pigs.
• Kinetana Hong Kong Herbal Pharmaceutical Ltd. is a subsidiary of Edmontonbased Kinetana Group Inc. Kinetana is involved in a research partnership with the Biotechnology Research Institute and also signed a research agreement with the Hong Kong Institute of Biotechnology in January 2000. The company has set up a sophisticated research and development laboratory at HKIB to developherbal pharmaceuticals.

Export Checklist

• While there are no significant regulatory or legal barriers for Canadian firms to overcome when conducting business in Hong Kong, companies will benefit from the experience and contacts of a local business advisor who is familiar with both the biotechnology industry and the manner in which business is conducted in Hong Kong.
• All pharmaceutical companies must be registered to operate in Hong Kong and all manufactured or imported pharmaceutical products must be licensed by the Pharmacy and Poisons Board at the Department of Health. Products exempt from registration include products consisting entirely of Chinese herbal medicines, raw materials imported for manufacturing, and products intended for re-export.
• In January 2002, China's Ministry of Agriculture ruled that overseas firms exporting biotechnology products to China must apply for certificates stating that the products are harmless to humans, animals and the environment. As of March 2002, new regulations were issued requiring food for sale containing genetically modified ingredients be labeled. Some of the main products affected by this regulation include soybeans, corn, canola, cottonseed, and tomatoes.

Key Contacts

Canadian Government Contacts

Consulate General of Canada in Hong Kong
G.P.O. Box 11142
Central, Hong Kong
Tel.: (852) 2847-7414
Fax: (852) 2847-7441
Contact: Fatima Lai, Commercial Officer
E-mail: fatima.lai@dfait-maeci.gc.ca
Internet: http://www.hongkong.gc.ca

Agriculture and Agri-Food Canada
Market and Industry Services Branch
Sir John Carling Building
930 Carling Ave.
Ottawa, ON K1A 0C5
Tel.: (613) 759-7744
Fax: (613) 759-7499
Internet: http://www.agr.ca

Canadian Food Inspection Agency
Office of Biotechnology
59 Camelot Dr.
Nepean, ON K1A 0Y9
Tel.: (613) 225-2342
Fax: (613) 228-6653
E-mail: cfiamaster@agr.gc.ca
Internet: http://www.cfia-acia.agr.ca

Export Development Canada (EDC)
151 O'Connor St.
Ottawa, ON K1A 1K3
Tel.: 1-888-332-3320 or (613) 598-2500
Fax: (613) 237-2690
E-mail: export@edc-see.ca
Internet: http://www.edc-see.ca

Health Canada
International Affairs Directorate
Brooke Claxton Building, Room 814A
Postal Locator 0908A
Tunney's Pasture
Ottawa, ON K1A 0K9
Tel.: (613) 941-3136
Fax: (613) 952-7417
Internet: http://www.hc-sc.gc.ca

Department of Foreign Affairs and International Trade (DFAIT)
125 Sussex Dr.
Ottawa, ON K1A 0G2
Internet: http://www.dfait-maeci.gc.ca
China and Mongolia Division (PCM)
Tel.: (613) 996-7177
Fax: (613) 943-1068
Contact: Jeremy Wallace, Desk Officer
E-mail: jeremy.wallace@dfait-maeci.gc.ca
Market Research Centre (TCM)
Tel.: (613) 996-3535
Fax: (613) 943-1103
Contact: Michelle Van Dyk, International Market
Research Officer
E-mail: michelle.van-dyk@dfait-maeci.gc.ca
Internet: http://www.infoexport.gc.ca
Market Support Division (TCM)
Tel.: (613) 996-1431
Fax: (613) 944-0050
Contact: Patricia Filteau, Trade Commissioner
E-mail: patricia.filteau@dfait-maeci.gc.ca

Industry Canada
Life Sciences Branch
PO Box 940, Station M
1505 Barrington St.
Halifax, NS B3J 2V9
Tel.: (902) 426-9958
Fax: (902) 426-2624
Contact: Mark Craig, Sector Officer
E-mail: craig.mark@ic.gc.ca
Internet: http://strategis.ic.gc.ca

Canadian Industry Associations

Ag-West Biotech
101 - 111 Research Dr.
Saskatoon, SK S7N 3R2
Tel.: (306) 975-1939
Fax: (306) 975-1966
E-mail: agwest@agwest.sk.ca
Internet: http://www.agwest.sk.ca

Ottawa Life Sciences Council
600 Peter Morand Dr., Suite 100
Ottawa, ON K1G 5Z3
Tel.: (613) 521-1008
Fax: (613) 521-3065
Internet: http://olsc.ca

Alberta Biotechnology Association
1150, 10180-101 St.
Edmonton, AB T5J 3S4
Tel.: (780) 425-3815
Fax: (780) 423-3893
Contact: Myka Osinchuk, Executive Director
E-mail: myka@bioalberta.com
Internet: http://www.bioalberta.com

BioAtlantech
PO Box 636, Station A
Fredericton, NB E3B 5A6
Tel.: (506) 444-2444
Fax: (506) 444-5662
Internet: http://www.bioatlantech.nb.ca

BioEast
2nd Floor, Spencer Hall
220 Prince Philip Dr.
St. John's, NF A1B 3X5
Tel.: (709) 737-2682
Fax: (709) 737-4029
Contact: Margaret Miller, Managing Director
Internet: http://www.bioeast.ca

BIONova
c/o Innovacorp
101 Research Dr.
PO Box 790
Dartmouth, NS B2Y 3Z7
Tel.: (902) 424-8670
Fax: (902) 424-4679
Contact: Bill Mills, Executive Director
E-mail: bmills@innovacorp.ns.ca

Bio Quebec
6100 Avenue Royalmount
Montreal, QC H4P 2R2
Tel.: (514) 733-8411
Fax: (514) 733-8272
E-mail: info@bioquebec.com
Internet: http://www.bioquebec.com

BIOTECanada
130 Albert St., Suite 420
Ottawa, ON K1P 5G2
Tel.: (613) 230-5585
Fax: (613) 563-8850
E-mail: info@biotech.ca
Internet: http://www.biotech.ca

British Columbia Biotechnology Alliance
3250 East Mall, Suite 225
Vancouver, BC V6T 1W5
Tel.: (604) 221-3020
Fax: (604) 221-3027
Contact: Paul Stinson, Executive Director
Internet: http://www.bcbiotech.ca

Canada's Research-Based Pharmaceutical Companies
302-1111 Prince of Wales Dr.
Ottawa, ON K2C 3T2
Tel.: (613) 727-1380
Fax: (613) 727-1407
Internet: http://www.canadapharma.org

Canadian Chamber of Commerce in Hong Kong
Suite 1003 Kinwick Centre
32 Hollywood Road
Central, Hong Kong
Tel.: (852) 2110-8700
Fax: (852) 2110-8701
Internet: http://www.cancham.org

Toronto Biotechnology Initiative
PO Box 446, Station A
Toronto, ON M5W 1C2
Tel.: (416) 392-4780
Fax: (416) 397-0906
Internet: http://www.torontobiotech.org

Hong Kong Government Contacts

Commerce and Industry Bureau
Level 29, 1 Pacific Place, 88 Queensway
Central, Hong Kong
Tel.: (852) 2918-7500
Fax: (852) 2840-1621
E-mail: cibenq@cib.gov.hk
Internet: http://www.info.gov.hk/cib/ehtml/main.html

Department of Health
Wu Chung House, 17th and 21st Floors
213 Queen's Rd. East
Wanchai, Hong Kong
Tel.: (852) 2961-8989
Fax: (852) 2836-0071
E-mail: dhenq@dh.gcn.gov.hk
Internet: http://www.info.gov.hk/dh

Health and Welfare Bureau
Murray Building, 19th and 20th Floors
Garden Rd.
Central, Hong Kong
Tel.: (852) 973-8168
Fax: (852) 2840-0467 or 541-3352
E-mail: hwbenq@hwb.gcn.gov.hk
Internet: http://www.info.gov.hk/hwb

Hong Kong Trade Development Council
38th Floor, Office Tower, Convention Plaza
1 Harbour Road
Wanchai, Hong Kong
Tel.: (852) 2584 4333
Fax: (852) 2824 0249
E-mail: hktdc@tdc.org.hk
Internet: http://www.tdctrade.com

Hong Kong Economic Trade Office in Canada
Toronto
174 St. George St.
Toronto, ON M5R 2M7
Tel.: (416) 924-5544
Fax: (416) 924-3599
E-mail: etotor@hketo.ca
Internet: http://www.hketo.ca
Vancouver
666 Burrard St. Suite 1300 Park Palace
Vancouver BC V6C 3J8
Tel.: (604) 331-1300
Fax: (604) 331-1368

Innovation and Technology Commission (ITC)
14th Floor Ocean Centre
5 Canton Road, Tsim Sha Tsui
Kowloon, Hong Kong
Tel.: (852) 2737-2208
Fax: (852) 2730-4633
Internet: http://www.info.gov.hk/itc/index.html

Invest Hong Kong
Government of the Hong Kong Special
Administrative Region,
Level 15, One Pacific Place
Queensway, Hong Kong
Tel.: (852) 3107-1000
Fax: (852) 3107-9007
E-mail: enq@InvestHK.gov.hk
Internet: http://investhk.gov.hk/ENG/index.htm

Trade and Industry Department
Trade and Industry Department Tower, Rm 908
700 Nathan Road
Kowloon, Hong Kong
Tel.: (852) 2392-2922
Fax: (852) 2787-7422
Internet: http://www.info.gov.hk/tid/e-index.htm

Hong Kong Industry Contacts and Research Centres

Applied Research Centre for Genomics Technology (ACGT)
City University of Hong Kong
83 Tat Chee Avenue
Kowloon Tong, Hong Kong
Tel.: (852) 2788-7797
Fax: (852) 2788-7406
Internet: http://www.biochip.com.hk

Biotechnology Research Institute (BRI)
Hong Kong University of Science and Technology
Clear Water Bay
Kowloon, Hong Kong
Tel.: (852) 2358-8781
Fax: (852) 2719-1273
Internet: http://www.ust.hk/~bri/index.shtml

Hong Kong Association of the Pharmaceutical Industry
Rm A, 13/F Trust Tower
68 Johnston Road
Wanchai, Hong Kong
Tel.: (852) 2528-3061 or (852) 2528 3062
Fax: (852) 2865-6283
Internet:
http://www.fmshk.com.hk/hkapi/index.htm

Hong Kong Applied Science and Technology Research Institute Co. Ltd. (ASTRI)
18/F, Tower 6 Gateway
9 Canton Road, Tsimshatsui
Kowloon, Hong Kong
Tel.: (852) 3406 2800
Fax: (852) 3406 2801
Internet: http://www.astri.org

Hong Kong Institute of Biotechnology Ltd. (HKIB)
2 Biotechnology Avenue
12 Miles, Tai Po Road
Shatin, N.T., Hong Kong
Tel.: (852) 2603-5111
Fax: (852) 2603-5012
Internet: http://www.hkib.org.hk

Hong Kong Biotechnology Association
Rm 789, HITEC, 1 Trademart Drive
Kowloon Bay
Kowloon, Hong Kong
Tel.: (852) 2620-9955 or (852) 2620 9988
Fax: (852) 2620-1238
Internet: http://www.hkbta.org.hk

Hong Kong Jockey Club Institute of Chinese Medicine Ltd
18/F Tower 6 Gateway
9 Canton Road, Kowloon
Hong Kong
Tel: (852) 3406 2872
Fax: (852)3406 2801

Hong Kong Productivity Council
HKPC Building
78 Tat Chee Avenue, Kowloon
Hong Kong
Tel: (852) 2788 5514 or (852)2788 5678
Fax: (852) 2788 5522
Internet: http://www.hkpc.org

Hong Kong Science and Technology Parks Corporation
Suites 3402-06, 34/F Tower One
The Gateway
9 Canton Road
Kowloon, Hong Kong
Tel.: (852) 2629-1818
Fax: (852) 2629-1833
Internet: http://www.hkstp.org

References

Avery, Bryant. "A Piece of the Bio-Tech Pie: Yeast Spans $2 billion Venture to Make Green Fertilizer," Edmonton Journal, December 2001.

Benitez, Mary Ann. "SAR Grapples with Laws of Nature," South China Morning Post, December 2001.

Canada. Export Development Canada. "Hong Kong," EDC Economic Overview. Downloaded on November 29, 2001 from: http://www.edc-see.ca. (Users must register to access specific documents)

Cyranoski, David. "Putting the pieces together". Nature Publishing Group, July 2001. Downloaded on March 8, 2002 from:
http://www.nature.com/naturejobs/spotlight/
hongkong/indexregions.html.

Easen, Nick. "Sowing seeds of dispute in China". CNN.com/World, January 2002. Downloaded on March 8, 2002 from:
http://asia.cnn.com/2002/WORLD/asiapcf/east/
01/07/china.gmfoods

Economist Intelligence Unit. "Hong Kong Economic Forecast," December 18, 2001.

-----. "Hong Kong Economic Structure," July 5, 2001.

Einhorn, Bruce. "Hanging Hong Kong's Future on...Biotech?" BusinessWeek online, March 18, 2002. Downloaded on March 22, 2002 from:
http://www.businessweek.com/bwdaily/dnflash/
mar2002/nf20020318_0352.htm.

Hong Kong. Innovation and Technology Commission. "Biotechnology". Downloaded on January 17, 2002 from:
http://www.info.gov.hk/itc/eng/technology/
biotechnology.shtml.

Hong Kong. Invest Hong Kong. "Biotechnology". Downloaded on January 17, 2002 from: http://investhk.gov.hk/ENG_text/SEC/
TAG_SEC/TEC/biotech.htm.

Hong Kong University of Science and Technology. Biotechnology Research Institute. "Current Research Projects," 2002. Downloaded on April 4, 2002 from: http://www.ust.hk/~bri/projects.html.

Marketletter. "Asian Pharma Market and Industry Development Prospects to 2005," October 2001.

Yau, Winston. "Maxx Eyes Biotech Foothold," South China Morning Post, November 2001.

Yeung, Linda. "Universities sign GM Research Pact," South China Morning Post, September 2001.

¹  For contact information regarding key organizations mentioned in this report, see Key Contacts.

² All monetary amounts are expressed in Canadian dollars, unless otherwise indicated. The conversion rate to Canadian dollars is based on IDD Information Services, Tradeline, April 2002.